Test Price
2,800 AED✅ Home Collection Available
DDHD1 Gene SPG28 Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- ✔ Diagnostic Accuracy:99.9% analytical sensitivity for SNV and small indels via ISO‑certified NGS pipeline.
- ✔ Logistics:VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily 8 AM–11 PM.
- ✔ Clinical Guidance:Post‑test telephone counselling by a consultant medical geneticist.
- ✔ Insurance:Direct coverage verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The DDHD1 gene NGS test provides a comprehensive analysis of the DDHD1 gene, responsible for autosomal recessive hereditary spastic paraplegia type 28 (SPG28). This neurodegenerative condition typically presents with progressive lower limb spasticity and weakness. Our assay offers definitive molecular diagnosis, carrier detection, and facilitates informed family planning decisions, utilising the highest precision Next‑Generation Sequencing technology.
| Feature | Our DDHD1 SPG28 NGS Test | Closest Alternative (Targeted Sanger) |
|---|---|---|
| Analytical Sensitivity | >99.9% for single nucleotide variants & small indels | ~98% (misses deep intronic mutations) |
| Methodology | Full‑gene NGS with copy number variant (CNV) detection | Sanger sequencing of coding exons only |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
| Sample Options | Blood, Extracted DNA, or FTA Card Spot | Whole Blood only |
| Price | 2800 AED | 3200‑3500 AED |
Physician Insight & Safety Protocols
“A molecular diagnosis of SPG28 is not just a laboratory finding—it is a pivotal moment for your family’s neurological future. While this test offers near‑definitive clarity, results must be interpreted alongside your complete clinical picture by a specialist neurologist or geneticist. Please remember: a negative result does not exclude all forms of hereditary spastic paraplegia, and a positive result should prompt early intervention and family screening.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Pre‑Test Advisory
Clinical Notice: Do not discontinue any prescribed medication without consulting your doctor. This test does not replace ongoing neurological care.
Patient Safety Exclusion Criteria & Red Flags
- Current acute neurological deterioration (e.g., sudden vision loss, severe ataxia) – seek immediate emergency care.
- Patients with unstable psychiatric conditions who lack capacity for informed genetic consent – require a legal guardian.
- Minors below 14 years without parental/guardian consent and mandatory genetic counselling as per UAE law.
- Individuals unable to provide a valid blood sample due to contraindicated anticoagulation therapy (discuss with phlebotomist).
- If requested for deceased relative’s DNA extraction, additional legal clearance under UAE PDPL is mandatory.
Patient FAQ & Clinical Guidance
1. What does a positive DDHD1 variant mean for my child’s development?
A positive pathogenic variant confirms genetic predisposition to SPG28, a treatable spastic paraplegia with early physiotherapy significantly improving gait and quality of life.
2. Is the 2800 AED fee covered by UAE insurance plans?
Most major UAE insurers (Daman, AXA, Neuron) reimburse genetic testing for hereditary spastic paraplegia when medically indicated and pre‑authorised by a neurologist.
3. How reliable is an FTA card sample compared to a blood draw?
An FTA card blood spot provides DNA stability identical to fresh blood, yielding >99.9% successful sequencing rates when collected correctly using our ISO‑certified protocol.
UAE Regulatory & Data Privacy Adherence
This test complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted and processed in accordance with DHA regulations. The laboratory is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | DDHD1 Gene SPG28 Genetic Test |
| Price (AED) | 2800 |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral whole blood, Extracted DNA, or FTA Card Spot |
| Methodology Used | Full‑gene Next‑Generation Sequencing (NGS) with CNV detection |
| ICD-10-CM Code | G11.4 |
| LOINC Code | 91809-7 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians